Data sourcesSEC FORM 443s ago
HOUSE PTR23s ago
SEC 13F16s ago
ROBINHOOD CHAIN8s ago
Public company
AVTXAvalo Therapeutics, Inc.
CIK 0001534120
Disclosed transactions60
Buys / sells0 / 23
Max Insider Score38
Connections10with evidence
AVTX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | | AVTXAvalo Therapeutics, Inc. Grant or award | A | $14K 1,109 sh | Sep 30, 2026 | Oct 2, 2026 traded Sep 30, 2026 | +2d | SEC FORM 4 | |
|
3
SRSullivan Christopher RyanChief Financial Officer |
AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan |
| Sep 18, 2026 traded Sep 16, 2026 |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 12.4K sh | Sep 16, 2026 | Sep 18, 2026 traded Sep 16, 2026 | +2d | SEC FORM 4 | |
| 9 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $202K 12.4K sh | Sep 16, 2026 | Sep 18, 2026 traded Sep 16, 2026 | +2d | SEC FORM 4 | |
| 3 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $82K 10.2K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC FORM 4 | |
| 14 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $179K 10.2K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 10.2K sh | Sep 10, 2026 | Sep 11, 2026 traded Sep 10, 2026 | +1d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | Aug 28, 2026 | Sep 1, 2026 traded Aug 28, 2026 | +4d | SEC FORM 4 | |
| 3 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $14K 679 sh | Aug 28, 2026 | Sep 1, 2026 traded Aug 28, 2026 | +4d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | Aug 28, 2026 | Sep 1, 2026 traded Aug 28, 2026 | +4d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $13K 1,000 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 10 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $375K 37.9K sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 31.0K sh | Aug 18, 2026 | Aug 19, 2026 traded Aug 18, 2026 | +1d | SEC FORM 4 | |
| 22 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $622K 31.0K sh | Aug 18, 2026 | Aug 19, 2026 traded Aug 18, 2026 | +1d | SEC FORM 4 | |
| 22 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $753K 37.9K sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $28K 2,876 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,876 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 37.9K sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 10 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $307K 31.0K sh | Aug 18, 2026 | Aug 19, 2026 traded Aug 18, 2026 | +1d | SEC FORM 4 | |
| 15 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $75K 3,749 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 8 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $20K 1,000 sh | Aug 17, 2026 | Aug 19, 2026 traded Aug 17, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | Aug 10, 2026 | Aug 12, 2026 traded Aug 10, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | Aug 10, 2026 | Aug 12, 2026 traded Aug 10, 2026 | +2d | SEC FORM 4 | |
| 38 | RJRiley JenniferChief Strategy Officer | AVTXAvalo Therapeutics, Inc. Open-market sale | SELL | $52K 2,655 sh | Aug 11, 2026 | Aug 12, 2026 traded Aug 11, 2026 | +1d | SEC FORM 4 | |
| 8 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $14K 679 sh | Aug 10, 2026 | Aug 12, 2026 traded Aug 10, 2026 | +2d | SEC FORM 4 | |
| 9 | | AVTXAvalo Therapeutics, Inc. Grant or award | A | $1,038 69 sh | Jun 30, 2026 | Jul 2, 2026 traded Jun 30, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $26K 1,450 sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $12K 1,450 sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,450 sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC FORM 4 | |
| 9 | | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 40.2K sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC FORM 4 | |
| 9 | RJRiley JenniferChief Strategy Officer | AVTXAvalo Therapeutics, Inc. Tax withholding | F | $7,703 588 sh | Jun 10, 2026 | Jun 12, 2026 traded Jun 10, 2026 | +2d | SEC FORM 4 | |
| 9 | | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 20.1K sh | Jun 2, 2026 | Jun 4, 2026 traded Jun 2, 2026 | +2d | SEC FORM 4 | |
| 9 | | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 20.1K sh | Jun 2, 2026 | Jun 4, 2026 traded Jun 2, 2026 | +2d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $11K 679 sh | May 28, 2026 | Jun 1, 2026 traded May 28, 2026 | +4d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | May 28, 2026 | Jun 1, 2026 traded May 28, 2026 | +4d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | May 28, 2026 | Jun 1, 2026 traded May 28, 2026 | +4d | SEC FORM 4 | |
| 27 | RJRiley JenniferChief Strategy Officer | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 34.2K sh | May 21, 2026 | May 26, 2026 traded May 21, 2026 | +5d | SEC FORM 4 | |
| 20 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 43.5K sh | May 21, 2026 | May 26, 2026 traded May 21, 2026 | +5d | SEC FORM 4 | |
| 26 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $449K 18.6K sh | May 7, 2026 | May 11, 2026 traded May 7, 2026 | +4d | SEC FORM 4 | |
| 7 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $184K 18.6K sh | May 7, 2026 | May 11, 2026 traded May 7, 2026 | +4d | SEC FORM 4 | |
| 0 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 18.6K sh | May 7, 2026 | May 11, 2026 traded May 7, 2026 | +4d | SEC FORM 4 | |
| 26 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $230K 10.1K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 30 | | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $72K 3,167 sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | May 5, 2026 | May 7, 2026 traded May 5, 2026 | +2d | SEC FORM 4 | |
| 7 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 77.9K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 7 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 47.0K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 26 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $201K 8,900 sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 22 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $197K 9,219 sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 18 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $56K 2,700 sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 22 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $238K 12.3K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 25 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $257K 13.8K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 13 | SRSullivan Christopher RyanChief Financial Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $378K 47.0K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 3 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 28.6K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 0 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | May 5, 2026 | May 7, 2026 traded May 5, 2026 | +2d | SEC FORM 4 | |
| 29 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $426K 19.0K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 29 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $953K 44.9K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 18 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $98K 5,000 sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 25 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $496K 27.5K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
| 6 | DMDoyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $230K 28.6K sh | May 6, 2026 | May 7, 2026 traded May 6, 2026 | +1d | SEC FORM 4 | |
Chief Financial Officer · Mar 31, 2026